Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

NASDAQ: ONTX was reduced by Zacks.com  from a “get” rating to a “hold” score in a research note issued to capitalists on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It concentrates on discovering and creating little molecule medicine prospects to treat cancer. The Company‘s items under different stages of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of other equities research analysts likewise recently talked about the business. Noble Financial editioned a “get” score and also released a $11.00 rate objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and set a “buy” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. The business has a 50 day moving typical rate of $2.90 and also a two-hundred day relocating typical cost of $4.16. The firm has a market cap of $46.76 million, a P/E ratio of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly revenues results on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) profits per share for the quarter, covering experts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% as well as an adverse net margin of 8,294.27%. The firm had revenue of $0.06 million during the quarter, contrasted to the agreement estimate of $0.06 million. During the very same quarter in the prior year, the company uploaded ($ 0.45) EPS. En masse, research analysts anticipate that Onconova Therapeutics will certainly upload -1.18 EPS for the current year.

A variety of hedge funds have just recently bought and sold shares of ONTX. GSA Resources Allies LLP purchased a new setting in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Funding Administration LP purchased a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC acquired a brand-new placement in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC bought a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Lastly, Dimensional Fund Advisors LP got a new placement in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds as well as various other institutional capitalists possess 13.36% of the business’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which participates in the recognition as well as development of oncology therapeutics. It focuses on finding and also creating small particle medicine prospects to deal with cancer cells. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a cost-free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

For more information about research offerings from Zacks Investment Research, go to Zacks.com.

This instantaneous information alert was created by narrative scientific research innovation as well as economic information from Market in order to provide viewers with the fastest as well as most precise coverage. This tale was assessed by Market’s editorial group prior to publication. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS RIGHT NOW?

Prior to you take into consideration Onconova Therapeutics, you’ll intend to hear this.

Market keeps track of Wall Street’s premier and finest doing research analysts and also the stocks they suggest to their clients each day. Market has actually determined the 5 stocks that top analysts are quietly murmuring to their clients to acquire currently before the broader market catches on … and also Onconova Therapeutics had not been on the list.

While Onconova Therapeutics presently has a “Buy” ranking amongst experts, premier analysts believe these 5 stocks are much better buys.